These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21417835)

  • 1. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
    Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant: a review of its use in the prevention of nausea and vomiting.
    Curran MP; Robinson DM
    Drugs; 2009; 69(13):1853-78. PubMed ID: 19719336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
    Sarcev T; Secen N; Zaric B; Milovancev A
    J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Moore S; Tumeh J; Wojtanowski S; Flowers C
    Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
    Prommer E
    J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
    Jordan K; Jahn F; Jahn P; Behlendorf T; Stein A; Ruessel J; Kegel T; Schmoll HJ
    Bone Marrow Transplant; 2011 Jun; 46(6):784-9. PubMed ID: 20838387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Dando TM; Perry CM
    Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.